tert-butyl [(2-methylpropan-2-yl)oxycarbonyl-[(E)-3-[3-(pyridin-2-ylmethoxy)phenyl]but-2-enyl]amino] carbonate | 1025939-86-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl [(2-methylpropan-2-yl)oxycarbonyl-[(E)-3-[3-(pyridin-2-ylmethoxy)phenyl]but-2-enyl]amino] carbonate
• CAS: 1025939-86-9
• 化学式: C₂₆H₃₄N₂O₆
• 分子量: 470.566
• InChiKey: UGHXAVSOGDNKBS-XMHGGMMESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  34
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  87.2
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  tert-butyl [(2-methylpropan-2-yl)oxycarbonyl-[(E)-3-[3-(pyridin-2-ylmethoxy)phenyl]but-2-enyl]amino] carbonate 在 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 2-{3-[3-(Pyridin-2-ylmethoxy)-phenyl]-but-2-enyl}-[1,2,4]oxadiazolidine-3,5-dione
  参考文献：
  名称：

  Design and synthesis of oxadiazolidinediones as inhibitors of plasminogen activator inhibitor-1

  摘要：

  A novel series of PAI-1 inhibitors containing an oxadiazolidinedione moiety were identified by high through-put screening. Optimization of substituents by parallel synthesis and the iterative design toward understanding structure-activity relationship to improve potency are described. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.058
• 作为产物：
  描述：

  2-((3-bromophenoxy)methyl)pyridine 在 正丁基锂 、 jones reagent 、 sodium hydride 、 二异丁基氢化铝 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 生成 tert-butyl [(2-methylpropan-2-yl)oxycarbonyl-[(E)-3-[3-(pyridin-2-ylmethoxy)phenyl]but-2-enyl]amino] carbonate
  参考文献：
  名称：

  Design and synthesis of oxadiazolidinediones as inhibitors of plasminogen activator inhibitor-1

  摘要：

  A novel series of PAI-1 inhibitors containing an oxadiazolidinedione moiety were identified by high through-put screening. Optimization of substituents by parallel synthesis and the iterative design toward understanding structure-activity relationship to improve potency are described. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.058

文献信息

• New Azolidinediones as Inhibitors of Protein Tyrosine Phosphatase 1B with Antihyperglycemic Properties
  作者：Michael S. Malamas、Janet Sredy、Iwan Gunawan、Brenda Mihan、Diane R. Sawicki、Laura Seestaller、Donald Sullivan、Brenda R. Flam

  DOI：10.1021/jm990476x

  日期：2000.3.1

  Insulin resistance in the liver and peripheral tissues together with a pancreatic cell defect are the common causes of type 2 diabetes. It is now appreciated that insulin resistance can result from a defect in the insulin receptor signaling system, at a site post binding of insulin to its receptor. Protein tyrosine phosphatases (PTPases) have been shown to be negative regulators of the insulin receptor. Inhibiton of PTPase may be an effective method in the treatment of type 2 diabetes. A series of azolidinediones has been prepared as protein tyrosine phosphatase 1B (PTP1B) inhibitors. Several compounds were potent inhibitors against the recombinant rat and human PTP1B enzymes with submicromolar IC50 values. Elongated spacers between the azolidinedione moiety and the central aromatic portion of the molecule as well as hydrophobic groups at the vicinity of this aromatic region were very important to the inhibitory activity. Oxadiazolidinediones 87 and 88 and the corresponding acetic acid analogues 119 and 120 were the best h-PTP1B inhibitors with IC50 values in the range of 0.12-0.3 mu M. Several compounds normalized plasma glucose and insulin levels in the ob/ob and db/db diabetic mouse models.
• Design and synthesis of oxadiazolidinediones as inhibitors of plasminogen activator inhibitor-1
  作者：Ariamala Gopalsamy、Scott L. Kincaid、John W. Ellingboe、Thomas M. Groeling、Thomas M. Antrilli、Girija Krishnamurthy、Ann Aulabaugh、Gregory S. Friedrichs、David L. Crandall

  DOI：10.1016/j.bmcl.2004.04.058

  日期：2004.7

  A novel series of PAI-1 inhibitors containing an oxadiazolidinedione moiety were identified by high through-put screening. Optimization of substituents by parallel synthesis and the iterative design toward understanding structure-activity relationship to improve potency are described. (C) 2004 Elsevier Ltd. All rights reserved.